Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has announced the completion of dose-escalation stage of the on-going Phase I/II clinical study for BL-7010, a non-absorbable, an orally available polymer intended for the treatment of celiac disease.
Subscribe to our email newsletter
No dose-limiting safety issues and no serious adverse events have been reported in the dose-escalation stage. Based on these encouraging safety and tolerability results, BioLineRx will proceed with the repeated administration stage, in which each patient will receive either BL-7010 or placebo for 14 days, three times per day. Results are anticipated in mid-2014.
The Phase I/II study, which is being conducted at Tampere Hospital in Finland, is a two-part (single and repeated administration) double-blind, dose escalation study of BL-7010 in up to 24 well-controlled celiac patients.
Primary objective of the placebo-controlled study is to evaluate the safety of single and repeated ascending doses of BL-7010, while secondary objectives include an assessment of the systemic exposure, if any, of BL-7010 in the study patients.
During the first part of the study, six dose levels of BL-7010 were evaluated compared to placebo. The escalation stage reached the highest planned dose.
BioLineRx CEO Dr Kinneret Savitsky noted BL-7010 for the treatment of celiac disease is one of the company’s lead development programs, and it is very happy to see that it is safe and well tolerated – even at very high doses that are significantly above the expected clinical efficacious dose.
"BL-7010 is a unique and very promising product, with excellent pre-clinical efficacy and safety results. We expect to report the full results of the current Phase 1/2 study in mid-2014 and assuming they are successful, we expect to commence a randomized, controlled efficacy study in celiac patients by the end of this year," Savitsky added.
Safety and efficacy of BL-7010 was demonstrated in pre-clinical studies.
BL-7010 was invented by Dr Jean-Christophe Leroux from ETH Zurich, Switzerland, Institute of Pharmaceutical Sciences department of Chemistry and Applied Biosciences. The drug is being developed by BioLineRx under a worldwide exclusive license agreement with Univalor.